Terms: = Endocrine gland cancer AND PALB2, ENSG00000083093, 79728
322 results:
1. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
2. A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
Jamison JK; May MS; Raufi AG; Luk L; Wong W; Mundi PS; Manji GA
Oncologist; 2024 Apr; 29(4):350-355. PubMed ID: 38394390
[TBL] [Abstract] [Full Text] [Related]
3. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
4. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract] [Full Text] [Related]
5. Targeting BRCA and palb2 in Pancreatic cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract] [Full Text] [Related]
6. Genetic predisposition to differentiated thyroid cancer in the Polish population.
Borowczyk M; Sypniewski M; Szyda J; Braszka M; Ziemnicka K; Ruchała M; Oszywa M; Król ZJ; Dobosz P
Pol Arch Intern Med; 2024 Mar; 134(3):. PubMed ID: 38165228
[TBL] [Abstract] [Full Text] [Related]
7. Cost-Effectiveness Analysis of Screening for Pancreatic cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract] [Full Text] [Related]
8. Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy.
Micaily I; Blais EM; Carhart R; Lam S; Cohen SJ; Cannaday SJ; Halverson D; Matrisian LM; DeArbeloa P; Thach D; Petricoin E; Pishvaian MJ; Lavu H; Yeo CJ; Mallick AB
JCO Precis Oncol; 2023 Sep; 7():e2200648. PubMed ID: 38085059
[TBL] [Abstract] [Full Text] [Related]
9. Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and palb2 germline mutations.
Infante M; Arranz-Ledo M; Lastra E; Olaverri A; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Clin Chim Acta; 2024 Jan; 552():117695. PubMed ID: 38061684
[TBL] [Abstract] [Full Text] [Related]
10. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract] [Full Text] [Related]
11. Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast cancer.
Lynce F; Robson M
Cancer Treat Res; 2023; 186():91-102. PubMed ID: 37978132
[TBL] [Abstract] [Full Text] [Related]
12. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic cancer.
Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
JCO Precis Oncol; 2023 Sep; 7():e2300152. PubMed ID: 37944072
[TBL] [Abstract] [Full Text] [Related]
13. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Daly MB; Pal T; Maxwell KN; Churpek J; Kohlmann W; AlHilli Z; Arun B; Buys SS; Cheng H; Domchek SM; Friedman S; Giri V; Goggins M; Hagemann A; Hendrix A; Hutton ML; Karlan BY; Kassem N; Khan S; Khoury K; Kurian AW; Laronga C; Mak JS; Mansour J; McDonnell K; Menendez CS; Merajver SD; Norquist BS; Offit K; Rash D; Reiser G; Senter-Jamieson L; Shannon KM; Visvanathan K; Welborn J; Wick MJ; Wood M; Yurgelun MB; Dwyer MA; Darlow SD
J Natl Compr Canc Netw; 2023 Oct; 21(10):1000-1010. PubMed ID: 37856201
[TBL] [Abstract] [Full Text] [Related]
14. Ethnicity-specific BRCA1, BRCA2, palb2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
Sokolenko AP; Bakaeva EK; Venina AR; Kuligina ES; Romanko AA; Aleksakhina SN; Belysheva YV; Belogubova EV; Stepanov IA; Zaitseva OA; Yatsuk OS; Togo AV; Khamgokov ZM; Kadyrova AO; Pirmagomedov AS; Bolieva MB; Epkhiev AA; Tsutsaev AK; Chakhieva MD; Khabrieva KM; Khabriev IM; Murachuev MA; Buttaeva BN; Baboshkina LS; Bayramkulova FI; Katchiev IR; Alieva LK; Raskin GA; Orlov SV; Khachmamuk ZK; Levonyan KR; Gichko DM; Kirtbaya DV; Degtyariov AM; Sultanova LV; Musayeva HS; Belyaev AM; Imyanitov EN
Breast Cancer Res Treat; 2024 Jan; 203(2):307-315. PubMed ID: 37851290
[TBL] [Abstract] [Full Text] [Related]
15. Association of Glycated Hemoglobin With a Risk of Pancreatic cancer in High-Risk Individuals Based on Genetic and Family History.
Wu BU; Chen Q; Moon BH; Lustigova E; Nielsen EG; Alvarado M; Ahmed SA
Clin Transl Gastroenterol; 2024 Jan; 15(1):e00650. PubMed ID: 37800692
[TBL] [Abstract] [Full Text] [Related]
16. Deciphering the Pathways to PARP Sensitivity in Pancreatic cancer.
Tsang ES; Gallinger S
Clin Cancer Res; 2023 Dec; 29(24):5005-5007. PubMed ID: 37787975
[TBL] [Abstract] [Full Text] [Related]
17. Mosaic
Schwartz M; Ibadioune S; Chansavang A; Vacher S; Caputo SM; Delhomelle H; Wong J; Abidallah K; Moncoutier V; Becette V; Popova T; Suybeng V; De Pauw A; Stern MH; Colas C; Mouret-Fourme E; Stoppa-Lyonnet D; Golmard L; Bieche I; Masliah-Planchon J
J Med Genet; 2024 Feb; 61(3):284-288. PubMed ID: 37748860
[TBL] [Abstract] [Full Text] [Related]
18. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.
Bhattacharya R; Ghosh A; Mukhopadhyay S
Mol Biol Rep; 2023 Nov; 50(11):9511-9519. PubMed ID: 37737967
[TBL] [Abstract] [Full Text] [Related]
19. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).
Fernández Madrigal L; Rodríguez Garcés MY; Jiménez Ruiz FJ
Curr Probl Cancer; 2023 Dec; 47(6):101008. PubMed ID: 37704491
[TBL] [Abstract] [Full Text] [Related]
20. Report on the Effect of the Implementation of an Early Detection and Prevention of cancer Program on Families at High Hereditary Risk-Concentrating on Patients Undergoing Genetic Diagnostics and Counseling in Central Poland.
Kałużewski T; Kubiak I; Bednarek M; Sałamunia J; Kucharska D; Kępczyński Ł; Stempień M; Kubicki T; Trzciński R; Gordon-Sönmez Z; Bartosińska-Dyc A; Gach A; Kałużewski B
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685988
[TBL] [Abstract] [Full Text] [Related]
[Next]
